DJIA 18,135.72 38.82 0.21%
NASDAQ 4,982.81 15.67 0.32%
S&P 500 2,101.04 2.51 0.12%
market minute promo

ArQule, Inc. (NASDAQ: ARQL)



company name or ticker

A Close Look At ArQule

Data on ArQule's Tivantinib - Analyst Blog

Data on ArQule's Tivantinib - Analyst Blog

ArQule (ARQL) Jumps: Stock Rises 6.8% - Tale of the Tape

This Week in Biotech: Clinical Trials and Tribulations

The J.P. Morgan Healthcare Conference led to the release of five important clinical updates this week.

ArQule Up on Study Results - Analyst Blog

ArQule Up on Study Results - Analyst Blog

Healthcare Stocks Declining; ArQule Jumps After Data Committee Signs Off On Continued Study of Cance

Healthcare Stocks Declining; ArQule Jumps After Data Committee Signs Off On Continued Study of Cancer Medication

Sector Update: Healthcare

Benzinga's Top #PreMarket Gainers

Why ArQule Inc. Shares Surged in After-Hours Trading

ArQule shares surge 26% after updating clinical trial data for key cancer drug tivantinib.

RedHill Biopharma Sells ADS - Analyst Blog

See More Articles...